Loading organizations...
NBGI Ventures builds a specialized portfolio of innovative medical technology companies, functioning as a venture capital firm providing capital and strategic oversight to early and mid-stage enterprises. It identifies high-potential medtech startups, performs due diligence, and guides their development from concept to commercialization across healthcare.
The firm was established in 2001 by Aris Constantinides, its Investment Director. This initiative stemmed from a significant equity gap within the European medical device industry, particularly for ventures needing specialized early-stage financing. Constantinides leveraged his extensive healthcare investment background to forge an entity focused on fostering medical advancements.
NBGI Ventures primarily serves medical technology entrepreneurs seeking capital and strategic acumen to advance their solutions. Its vision is to propel global healthcare progress by investing in and accelerating transformative medical technologies. It aims to drive impactful innovation, addressing unmet medical needs and enhancing patient well-being globally.
NBGI Ventures has 2 tracked investments across 2 companies. The latest tracked deal is $48.3M Series B in CellNovo in February 2011.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 4, 2011 | CellNovo | $48.3M Series B | — | Advent Venture Partners, Auriga Partners, Credit Agricole Private Equity, Forbion, HealthCare Ventures, Nesta |
| Mar 30, 2010 | Reverse Medical | $14.0M Series B | — | BioStar Ventures, Early Stage Partners, Emergent Medical Partners, Getz Brothers, MedFocus Funds, South Australian Life Science Advancement Partnership, Wexford Capital |
